Xeomin® and Gait Related Mobility After Stroke
Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke
Who can join
Ages 18 to 79 · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit * No prior surgery to the lower limb * Able to walk at least 10 meters without physical assistance from another person and without an assistive device * Toe- ground clearance during swing phase without assistive device or orthoses * No treatment with botulinum toxin within the past 4 months Exclusion Criteria: * Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees * Participants with uncorrected hearing impairment * Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe * Speech language expression deficit (e.g., aphasia) * Absence of proprioception upon neurologic examination * Presence of fixed contractures in the upper or lower extremities not correctable to neutral * Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)
About the study
The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).
What is being tested
- Xeomin® (drug)
Sponsor: Wake Forest University Health Sciences · Participants: 20 · Started: Oct 19, 2021
Contact the study team
- Mark A Hirsch, PhD · Phone: 704-355-7673
- Kiandra Austrie, RN, BSN · Phone: 704-355-1525
Official record on ClinicalTrials.gov — NCT04908423
Locations in the U.S.
| North Carolina | Carolinas Rehabilitation, Charlotte |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.